NPCE

Rating buyAI Memo

NeuroPace

As of 2026-01-17/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-17 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Clinical readout / adoption milestone (assumed window) • 2026-12-31

Expected move: +38%

Biggest risk

Slower clinician adoption, reimbursement setbacks, or execution failures mute revenue and compress multiples toward the analyst low (15.0).

Invalidation

Break below $15 or thesis failure.

What would change my mind?

Accelerating implant volumes, broader reimbursement, and positive clinical readouts drive revenue growth and multiple expansion toward the analyst high (23.1).

Research note

Recommendation

buy

Confidence

medium

As of

2026-01-17

Base target

$19

p=60%

Bull target

$23

p=20%

Bear target

$15

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Next quarterly earnings / guidance update
Reimbursement / label expansion for the RNS system
Accelerating implant volumes, broader reimbursement, and positive clinical readouts drive revenue growth and multiple expansion toward the analyst high (23.1).

BearKey bullets

Commercial execution or manufacturing failures
Competition from larger device manufacturers
Payer reimbursement delays or denials

WatchKey bullets

Clinical readout / adoption milestone (assumed window)

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $19 (p=60%)

Bull/Bear spread: +69% / +10%

Vs latest close: Bull +69% · Base +38% · Bear +10%

Scenario probabilities

Bull Target: $23 (p=20%)Base Target: $19 (p=60%)Bear Target: $15 (p=20%)

Commentary

Aggregated analyst targets sit modestly above the current price (median 18.8 vs. anchor 16.94), implying cautious upside from consensus [#SERP-2]. Dispersion (15.0–23.1) reflects uncertainty on adoption and reimbursement; near-term sentiment will hinge on earnings, payer updates, and clinical readouts [#SERP-4][#SERP-7].

As of 2026-01-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Accelerating implant volumes, broader reimbursement, and positive clinical readouts drive revenue growth and multiple expansion toward the analyst high (23.1).

Bear Case

Slower clinician adoption, reimbursement setbacks, or execution failures mute revenue and compress multiples toward the analyst low (15.0).

Drivers

Scannable catalysts and supporting factors

Next quarterly earnings / guidance update
Reimbursement / label expansion for the RNS system

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-17Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$18.80

Range (USD)

$15.00 - $23.10

Count

Query: NeuroPace Inc Common (NPCE) analyst consensus price target high low average

Neuropace Inc Consensus Estimates (NPCE) - Investing.com NG
Search result #1
According to projections from 8 analysts, the average 12-month price target for Neuropace is 17.25, with a high estimate of 20 and a low estimate of 13. What Is ...
Open source
NeuroPace (NPCE) Stock Forecast and Price Target 2026
Search result #2
According to the 8 analysts' twelve-month price targets for NeuroPace, the average price target is $18.50. The highest price target for NPCE is $22.00, while ...
Extracted: $18.50, $22.00Open source
NeuroPace, Inc.: Target Price Consensus and Analysts ...
Search result #3
Consensus NeuroPace, Inc. Equities. NPCE. US6412881053. Advanced Medical ... Average target price. 19.25USD. Spread / Average Target. +17.45%. High Price ...
Extracted: $19.25Open source
NeuroPace, Inc. (NPCE) Stock Price, News, Quote & History
Search result #4
Find the latest NeuroPace, Inc. (NPCE) stock quote, history, news and other vital information to help you with your stock trading and investing.
Open source
NPCE - NeuroPace, Inc. (NasdaqGM) - Share Price and News - Fintel
Search result #5
The forecasts range from a low of $15.15 to a high of $23.10. A stock's price target is the price at which analysts consider it fairly valued with respect to ...
Extracted: $15.15, $23.10Open source
NEUROPACE INC (NPCE) Stock Price, Forecast & Analysis - Chartmill
Search result #6
NPCE Forecast & Estimates 14 analysts have analysed NPCE and the average price target is 19 USD. This implies a price increase of 13.42% is expected in the ...
Extracted: $19.00Open source

Scenarios

Bull Target (Scenario probability)

$23 / p=20% prob

Base Target (Scenario probability)

$19 / p=60% prob

Bear Target (Scenario probability)

$15 / p=20% prob

Price $14 as of 2026-07-29

Nearest Scenario: Bear (∆ 10%)

Targets vs latest close: Bull +69% · Base +38% · Bear +10%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-12-31
Clinical readout / adoption milestone (assumed window)
Assumed clinical or adoption milestone window through H2 2026; selected window end as the expected_date and noted assumption — outcome could drive medium-sized re-rating [#SERP-7].
Prob 25.00% • Move 20.00% • Priced-in 10.00%

Short-term Catalysts

Next few weeks

Next quarterly earnings / guidance update
2026-04-17
Upcoming quarterly report assumed within 90 days (used conservative date); market reaction likely to depend on implant volumes and FY guidance — assumption and estimate used in modeling (date estimate) [#SERP-4].
Prob 60% • Move 12% • Priced-in 40%

Long-term Catalysts

Months to a year

Reimbursement / label expansion for the RNS system
2027-01-17
Broader payer coverage or label/reimbursement wins would materially expand addressable market over multiple quarters; conservative 12‑month-plus timing used for long scenario [#SERP-1].
Prob 30% • Move 30% • Priced-in 20%

Risks

Commercial execution or manufacturing failures
Competition from larger device manufacturers
Payer reimbursement delays or denials
Slower procedure adoption and lower implant volumes

Peers

Symbol	Summary
MDT	Global medtech with an established neuromodulation franchise; useful benchmark for scale, payer access, and reimbursement dynamics.
BSX	Diversified device leader with wide hospital distribution — a proxy for implantable-device commercialization and channel reach.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: NeuroPace Inc Common (NPCE) analyst consensus price target high low average
Analysis date: 2026-01-17

AI Stock Memo: NPCE - NeuroPace - RankAlpha